Neurological Efficacy and Safety of Mesenchymal Stem Cells (Mscs) Therapy in People With Multiple Sclerosis (Pwms): An Updated Systematic Review and Meta-Analysis Publisher Pubmed

Summary: A study suggests stem cell therapy may help people with multiple sclerosis by improving MRI signs of nerve repair, though benefits remain uncertain and more research is needed. #MultipleSclerosis #StemCellResearch

Vaheb S¹ ; Afshin S² ; Ghoshouni H¹ ; Ghaffary EM¹ ; Farzan M³ ; Shaygannejad V^{1, 4} ; Thapa S⁵ ; Zabeti A⁶ ; Mirmosayyeb O^{1, 4}
Source: Multiple Sclerosis and Related Disorders Published:2024

Abstract

Background: Current therapeutic strategies for multiple sclerosis (MS) aim to suppress the immune response and reduce relapse rates. As alternative treatments, mesenchymal stem cells (MSCs) are being explored. MSCs show promise in repairing nerve tissue and reducing autoimmune responses in people with MS (pwMS). Objective: This review delves into the literature on the efficacy and safety of MSC therapy for pwMS. Methods: A comprehensive search strategy was employed to identify relevant articles from five databases until January 2024. The inclusion criteria encompassed interventional studies. Efficacy and safety data concerning MSC therapy in relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS) groups were extracted and analyzed. Results: A comprehensive analysis encompassing 30 studies revealed that individuals who underwent intrathecal (IT) protocol-based transplantation of MSCs experienced a noteworthy improvement in their expanded disability status scale (EDSS) compared to the placebo group. Weighted mean difference (WMD) was -0.28; 95 % CI -0.53 to -0.03, I2 = 0 %, p-value = 0.028); however, the intravenous (IV) group did not show significant changes in EDSS scores. The annualized relapse rate (ARR) did not significantly decrease among pwMS (WMD = -0.34; 95 % CI -1.05 to 0.38, I2 = 98 %, p-value = 0.357). Favorable results were observed in magnetic resonance imaging (MRI), with only 19.11 % of pwMS showing contrast-enhanced lesions (CEL) in the short term and no long-term MRI activity. The most common complications in both short-term and long-term follow-ups were infection, back pain, and gastrointestinal symptoms. Conclusions: The study highlights the safety potential of MSC therapy for pwMS. While MRI-based neural regeneration shows significant treatment potential, the effectiveness of MSC therapy remains uncertain due to study limitations and ineffective outcome measures. Further research is needed to establish efficacy and optimize evaluation methods for MSC therapy on pwMS. © 2024 Elsevier B.V.